/ Media

Press Releases

Discover the latest news about our company, our products, our policies, and our people.

1052 Results

Loading…

Date	Title
02 Jun 2013	Genentech's Medicine Avastin Plus Chemotherapy Improved Survival in Women with Advanced Cervical Cancer, Compared to Chemotherapy Alone
01 Jun 2013	Genentech Announces Final Phase III Study Results of Avastin Plus Radiotherapy and Chemotherapy in People with an Aggressive Form of Brain Cancer
15 May 2013	Genentech's Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer
14 May 2013	Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO
14 May 2013	FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer
30 Apr 2013	FDA Approves ACTEMRA^® for Children Living with a Rare Form of Arthritis
24 Feb 2013	Phase III Results Showed omalizumab Significantly Reduced Disease Severity in Patients with a Chronic form of Hives who Failed Standard Therapy
22 Feb 2013	FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating Her2-Positive Metastatic Breast Cancer
30 Jan 2013	Obinutuzumab (GA101) Significantly Improved Progression-Free Survival in People With Chronic Lymphocytic Leukemia (CLL)
23 Jan 2013	FDA Approves New Use of Avastin Plus Chemotherapy for People with Metastatic Colorectal Cancer
21 Dec 2012	Genentech Announces FDA Approval of Tamiflu for the Treatment of Influenza in Infants
07 Dec 2012	Genentech's Perjeta Significantly Extends Survival in People With HER2-Positive Metastatic Breast Cancer
17 Nov 2012	Genentech Study Showed That Avastin Helped People with Newly Diagnosed Glioblastoma Live Longer without Their Disease Worsening When Added to Radiation and Chemotherapy
10 Nov 2012	ADACTA Study Showed ACTEMRA Improved Signs and Symptoms of Rheumatoid Arthritis Significantly More Than Adalimumab as a Single-Agent Therapy
06 Nov 2012	FDA Grants Genentech's Trastuzumab Emtansine (T-DM1) Priority Review for HER2-Positive Metastatic Breast Cancer
12 Oct 2012	FDA Approves Expanded Indication for ACTEMRA^® in Rheumatoid Arthritis
01 Oct 2012	Genentech's Trastuzumab Emtansine (T-DM1) Significantly Extended Survival in People With Aggressive Form of Breast Cancer
26 Aug 2012	New Data from Phase III EMILIA Study Showed Genentech's Trastuzumab Emtansine (T-DM1) Significantly Improved Survival of People With HER2-Positive Metastatic Breast Cancer
10 Aug 2012	FDA Approves Lucentis^® (Ranibizumab Injection) for Treatment of Diabetic Macular Edema (DME)
09 Aug 2012	Genentech Study Showed That Adding Avastin to Radiation and Chemotherapy Significantly Extended the Time People with an Aggressive Form of Brain Cancer Lived without Their Disease Worsening
26 Jul 2012	Genentech Reports Second Positive Study of ACTEMRA® Given by Subcutaneous Injection to Patients with Rheumatoid Arthritis
26 Jul 2012	FDA Advisory Committee Unanimously Recommends Approval of Lucentis for Treatment of Diabetic Macular Edema (DME)
21 Jun 2012	New Data From Phase III Study Showed That People With HER2-Positive Metastatic Breast Cancer Lived Longer With Genentech's Perjeta
08 Jun 2012	FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer
05 Jun 2012	Genentech's ACTEMRA^® Improved Rheumatoid Arthritis Signs and Symptoms Significantly More Than Adalimumab as Single-Agent Therapy
02 Jun 2012	Genentech Data Showed That People With Metastatic Colorectal Cancer Lived Longer When They Continued on Avastin Plus Chemotherapy
02 Jun 2012	Genentech's Targeted Investigational Breast Cancer Medicine, Trastuzumab Emtansine (T-DM1), Reduced the Risk of Cancer Worsening or Death by 35 Percent in Pivotal Phase III Trial
01 Jun 2012	Genentech Study Showed That Adding Avastin to Chemotherapy Cut the Risk of the Disease Getting Worse in Difficult-to-Treat Recurrent Ovarian Cancer by Half
15 May 2012	Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
02 May 2012	Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection
29 Mar 2012	Genentech's Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer
01 Mar 2012	Genentech's ACTEMRA® Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy
07 Feb 2012	FDA Grants Genentech's Pertuzumab Priority Review for Previously Untreated HER2-Positive Metastatic Breast Cancer
30 Jan 2012	FDA Approves Erivedge (Vismodegib) Capsule, the First Medicine for Adults with Advanced Basal Cell Carcinoma
13 Jan 2012	Genentech Announces First Milestone Payment to Device-Maker ForSight VISION4, Inc. in Development of Sustained Delivery Lucentis
07 Dec 2011	Genentech Announces Positive Results of Pivotal Phase III Study with Pertuzumab in HER2-Positive Metastatic Breast Cancer
29 Nov 2011	Genentech to Present Important New Data for HER2-Positive Breast Cancer at 2011 San Antonio Breast Cancer Symposium
18 Nov 2011	FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer
08 Nov 2011	FDA Accepts Genentech's New Drug Application For Vismodegib in Advanced Form of Skin Cancer
05 Nov 2011	Data Showed ACTEMRA Monotherapy Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
19 Oct 2011	Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years
24 Sep 2011	Genentech's Investigational Medicine T-DM1 Showed Improvement in Progression-Free Survival Compared to Standard of Care in HER2-Positive Metastatic Breast Cancer
12 Sep 2011	Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer
17 Aug 2011	FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer
14 Jul 2011	Pertuzumab Combined with Herceptin and Chemotherapy Significantly Extended the Time People with HER2-Positive Metastatic Breast Cancer Lived without Their Disease Getting Worse
29 Jun 2011	Genentech Provides Update from FDA Hearing on Avastin for Metastatic Breast Cancer
28 Jun 2011	Two Pivotal Phase III Lucentis Studies Showed Patients With Diabetic Macular Edema Experienced Significant Improvements in Vision and Fewer Developed More Advanced Retinopathy
19 Jun 2011	Pivotal Study Showed Vismodegib Helped Shrink Tumors or Heal Lesions in People with Rare Form of Advanced Skin Cancer
04 Jun 2011	Genentech Announces Data to Show Avastin-Based Regimen Halved the Risk of Disease Getting Worse in Women with Recurrent Ovarian Cancer
05 Jun 2011	Genentech Announces Vemurafenib Improved Survival in People With Metastatic Melanoma Who Have BRAF V600 Mutations
02 Jun 2011	Tarceva Nearly Doubled the Time People with a Genetically Distinct Type of Lung Cancer Lived without Their Disease Getting Worse
18 May 2011	MetMAb in Combination with Tarceva Doubled the Time People with Lung Cancer Lived without Their Disease Getting Worse
17 May 2011	Genentech to Present Significant Progress in Advanced Skin, Lung and Ovarian Cancers at ASCO
10 May 2011	New Drug Applications Submitted in the United States and Europe for Vemurafenib in Advanced Skin Cancer
19 Apr 2011	FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
15 Apr 2011	FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
25 Mar 2011	Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema (DME)
20 Mar 2011	Genentech Announces Positive Pivotal Phase II Results for Hedgehog Pathway Inhibitor in Advanced Basal Cell Carcinoma
10 Mar 2011	Phase III Study of Lucentis Showed Rapid Vision Improvements Sustained for Two Years in Patients with Diabetic Macular Edema
24 Feb 2011	FDA Grants Genentech a Hearing on Avastin's Use for Metastatic Breast Cancer in the United States
11 Feb 2011	Lucentis Phase III Study Meets Primary Endpoint For Improving Vision In Patients With Diabetic Macular Edema (DME)
07 Feb 2011	Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
27 Jan 2011	Early Successful Readout of Tarceva Study in a Distinct Form of Lung Cancer
18 Jan 2011	Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
13 Jan 2011	Genentech Informs Customers of Important Information About Triad Group's Alcohol Prep Pads
05 Jan 2011	FDA Grants Supplemental Approval for ACTEMRA® (tocilizumab)
16 Dec 2010	Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
05 Dec 2010	Phase II Study with First-in-Class Investigational Drug Demonstrates Improvement in Negative Symptoms in Patients with Schizophrenia
10 Dec 2010	Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Women with Newly Diagnosed, Early-Stage HER2-Positive Breast Cancer
05 Dec 2010	Phase III Study Showed Rituxan® for Initial Use Followed by Continued Use Delayed the Need for Additional Therapy in People with Asymptomatic Follicular Lymphoma, a Common Type of Blood Cancer
28 Jan 2011	FDA Approves Rituxan for First-Line Maintenance Use in Follicular Lymphoma
07 Nov 2010	ACTEMRA Data Presented at ACR Annual Meeting on Rapid Response and Long-Term Efficacy in People with Rheumatoid Arthritis
04 Nov 2010	Genentech Reports Promising Phase II Results With New Targeted Approach in Advanced Melanoma
20 Oct 2010	FDA Approves Herceptin For HER2-Positive Metastatic Stomach Cancer
15 Oct 2010	Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
17 Sep 2010	Genentech Provides Update on Avastin for Advanced Breast Cancer
26 Aug 2010	Genentech Provides Update on FDA Application for T-DM1
10 Aug 2010	FDA Approves Longer Use of Valcyte for Adult Kidney Transplant Patients at High Risk of Developing Cytomegalovirus (CMV) Disease
20 Jul 2010	Genentech Provides Update From Avastin FDA Advisory Committee Meeting
06 Jul 2010	Genentech Submits Application to FDA for Trastuzumab-DM1 in Previously Treated Advanced HER2-Positive Breast Cancer
01 Jul 2010	Second Phase III Study Showed Avastin-Containing Regimen Helped Women with Ovarian Cancer Live Longer Without their Disease Getting Worse
22 Jun 2010	FDA Approves Lucentis® (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion
06 Jun 2010	Phase III Study Showed Avastin-Based Regimen Helped Women with Advanced Ovarian Cancer Live Longer Without Their Disease Worsening
03 Jun 2010	Genentech's Scheller Wins Kavli Prize in Neuroscience
20 May 2010	Phase III Study Showed First-Line Maintenance Use of Rituxan® Improved the Likelihood of People with Follicular Lymphoma Living without Their Disease Worsening
20 May 2010	Roche and Genentech to Present New Data on Different Approaches to Treating Cancer at ASCO
22 Apr 2010	Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
16 Apr 2010	FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
16 Mar 2010	Genentech Submits Supplemental Biologics License Application for ACTEMRA (tocilizumab) for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis
11 Mar 2010	Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer
24 Feb 2010	Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer
22 Feb 2010	Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
18 Feb 2010	FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
15 Jan 2010	FDA Extends Review Period for Tarceva Application for First-line Maintenance Use in Advanced Non-small Cell Lung Cancer
08 Jan 2010	FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
16 Dec 2009	FDA Advisory Committee Recommends Against Approving Tarceva for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
12 Dec 2009	New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast Cancer
11 Dec 2009	Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Women Previously Treated with Chemotherapy for Advanced Breast Cancer
10 Dec 2009	Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
07 Dec 2009	Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
18 Nov 2009	Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
16 Nov 2009	Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
17 Oct 2009	Genentech and Biogen Idec Receive a Complete Response from FDA for Earlier Use of Rituxan for Rheumatoid Arthritis
17 Oct 2009	Phase III Study Showed Two Years of ACTEMRA ® (tocilizumab) Inhibited Progression of Joint Damage and Improved Disease Remission
04 Oct 2009	Two Phase III Studies of Lucentis Show Early and Sustained Improvement in Vision in Patients with Retinal Vein Occlusion
16 Sep 2009	Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
17 Aug 2009	Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
02 Aug 2009	FDA Approves Avastin for the Most Common Type of Kidney Cancer
30 Jul 2009	Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein Occlusion
28 Jul 2009	Genentech Announces Appointment of Sandra J. Horning, M.D., to Senior Vice President, Global Head, Clinical Development Hematology/Oncology
19 Jul 2009	Xeloda®-Oxaliplatin Combination (Xelox) Shown to Be More Effective Than Standard Chemotherapy Regimen In Adjuvant Colon Cancer
12 Jul 2009	New Data from Phase III Saturn Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
02 Jul 2009	Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
30 May 2009	Phase III Study Showed Patients Lived Longer Without Advanced Lung Cancer Progressing When Tarceva Was Added to Avastin as First-Line Maintenance Therapy
30 May 2009	Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer
29 May 2009	Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer
19 May 2009	Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
14 May 2009	Genentech to Present Advances With Targeted Cancer Medicines at ASCO
05 May 2009	FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
21 Apr 2009	Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
08 Apr 2009	Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market
31 Mar 2009	FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Glioblastoma)
26 Mar 2009	Roche Completes Acquisition of Genentech
18 Mar 2009	OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
12 Mar 2009	Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
11 Mar 2009	Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
06 Mar 2009	Genentech Urges Stockholders to Take No Action With Respect to Revised Offer From Roche
24 Feb 2009	Genentech Receives Final Notification Upholding Cabilly Patent in Reexamination Proceeding
23 Feb 2009	Genentech Announces March 2, 2009 Webcast of Investment Community Meeting
23 Feb 2009	Genentech Special Committee Rejects Roche's $86.50 Offer as Inadequate
19 Feb 2009	National Coalition for Cancer Survivorship, UCLA, Wellpoint, and Genentech Launch Initiative to Provide Coordinated Follow-Up Care for People Surviving Cancer
09 Feb 2009	Genentech Urges Shareholders to Take No Action With Respect to Unsolicited Tender Offer from Roche
02 Feb 2009	Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer
30 Jan 2009	Special Committee of Genentech Board of Directors Responds to Roche's Announced Intention to Commence a Tender Offer
21 Jan 2009	Genentech Announces Vice President Appointment in Research
15 Jan 2009	Genentech Announces Full Year And Fourth Quarter 2008 Results
22 Dec 2008	Genentech Announces January 15 Webcast of Financial and Other Business Results
18 Dec 2008	Phase III Study Showed Rituxan Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis (RA)
06 Dec 2008	Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
23 Nov 2008	Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
17 Nov 2008	Genentech Issues Dear Healthcare Provider Letter Regarding a 2nd Case of PML in a Raptiva Patient
06 Nov 2008	Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
03 Nov 2008	Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer
27 Oct 2008	Rituxan Data in Patients With Rheumatoid Arthritis To Be Presented at The American College of Rheumatology Annual Scientific Meeting
19 Oct 2008	Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
14 Oct 2008	Genentech Announces Third Quarter 2008 Results
06 Oct 2008	Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
05 Oct 2008	Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
02 Oct 2008	Genentech, Glycart and Roche Enter Into Collaboration Agreement for Potential Cancer Therapy
02 Oct 2008	Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient
23 Sep 2008	Genentech Announces October 14 Webcast of Financial and Other Business Results
10 Sep 2008	Genentech Announces Vice President Appointment In Research
13 Aug 2008	Genentech Special Committee of Independent Directors Responds to Roche Proposal
24 Jul 2008	Genentech Forms Special Committee of Independent Directors to Review Roche Proposal
21 Jul 2008	Genentech Announces Receipt of Proposal From Roche
14 Jul 2008	Genentech Announces Second Quarter 2008 Results
23 Jun 2008	Genentech Announces July 14 Webcast of Financial and Other Business Results
11 Jun 2008	Genentech Settles Dispute Related To Cabilly Patent
31 May 2008	Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Women With Advanced HER2-Negative Breast Cancer
19 May 2008	Genentech Announces June 2 Webcast Discussion of Data Presented at ASCO
15 May 2008	Genentech Provides Update On Studies Of Investigational Biooncology Agents To Be Presented At The American Society Of Clinical Oncology Meeting
15 May 2008	Genentech Provides Update on Avastin Program
29 Apr 2008	Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
24 Apr 2008	Genentech Announces Decision In Contract Dispute
20 Apr 2008	Genentech Provides Update on "AVAiL" Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer
15 Apr 2008	Genentech Extends Stock Repurchase Program
14 Apr 2008	Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis
10 Apr 2008	Genentech Announces First Quarter 2008 Results
21 Mar 2008	Genentech Announces April 10 Webcast of Financial and Other Business Results
14 Mar 2008	Genentech Provides Business Update At Annual Investment Community Meeting
03 Mar 2008	Genentech Announces March 14 Webcast of Investment Community Meeting
25 Feb 2008	Genentech Receives Notification of Rejection of Cabilly Patent Claims From Reexamination Process
22 Feb 2008	FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
12 Feb 2008	Avado Study of Avastin Plus Docetaxel Chemotherapy Showed Improved Progression-Free Survival in Patients With Advanced Breast Cancer
24 Jan 2008	Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients With Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
14 Jan 2008	Genentech Announces Full Year and Fourth Quarter 2007 Results
20 Dec 2007	Genentech Announces January 14 Webcast Discussion of Financial and Other Business Results
05 Dec 2007	Genentech Provides Update From Avastin FDA Advisory Meeting
20 Nov 2007	Genentech Foundation for Biomedical Sciences Awards Nearly $1.2 Million to Health Science Education Programs in the Bay Area
18 Nov 2007	Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer
15 Oct 2007	Genentech Announces Third Quarter 2007 Results
24 Sep 2007	Genentech Announces October 15 Webcast Discussion of Earnings and Other Business Results
24 Aug 2007	Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer
02 Aug 2007	Genentech Announces Expiration of Hart-Scott-Rodino Waiting Period and Completes Acquisition of Tanox
11 Jul 2007	Genentech Announces Second Quarter 2007 Results
26 Jun 2007	Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology
20 Jun 2007	Genentech Announces July 11 Webcast Discussion of Earnings and Other Business Results
04 Jun 2007	Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
03 Jun 2007	Genentech Provides Update on Pipeline Agents at The American Society of Clinical Oncology Meeting
02 Jun 2007	Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients with Previously Untreated Advanced Kidney Cancer
02 Jun 2007	Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
11 May 2007	Genentech Announces June 4 Webcast Discussion of Data Presented at ASCO
01 May 2007	Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
20 Apr 2007	Genentech Extends Stock Repurchase Program
11 Apr 2007	Genentech Announces First Quarter 2007 Results
23 Mar 2007	Genentech to Provide Business Update at Annual Investment Community Meeting
21 Mar 2007	Genentech Announces April 11 Webcast Discussion of Earnings and Other Business Results
09 Mar 2007	Genentech Announces March 23 Webcast of Investment Community Meeting
21 Feb 2007	Analysis of International Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer
21 Feb 2007	Genentech Provides Update on Cabilly Patent Reexamination
14 Feb 2007	Genentech Announces Additional Effort to Support Patient Access
02 Feb 2007	Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis
29 Jan 2007	Genentech and Tanox Receive "Second Request" from the Federal Trade Commission
17 Jan 2007	Genentech Announces Senior Vice President and Vice President Promotions in Commercial, Legal and Product Operations
10 Jan 2007	Genentech Announces Full Year and Fourth Quarter 2006 Results
08 Jan 2007	Genentech Again Named One of FORTUNE's "100 Best Companies to Work For"
08 Jan 2007	Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40
04 Jan 2007	Genentech Announces Positive Results from a Randomized Phase II Study of Pertuzumab in Combination with Gemcitabine for Advanced Ovarian Cancer
20 Dec 2006	Genentech Announces January 10 Webcast Discussion of Earnings and Other Business Results
14 Dec 2006	Key Herceptin Data Presented at San Antonio Breast Cancer Symposium
13 Dec 2006	New England Journal of Medicine Publishes Data From Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer
11 Dec 2006	Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
16 Nov 2006	FDA Approves Herceptin for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
11 Nov 2006	Subsequent Course of Rituxan Improved Outcomes in Rheumatoid Arthritis Patients Who Inadequately Responded to TNF Antagonist Therapy
09 Nov 2006	Genentech Announces Agreement to Acquire Tanox for $20 Per Share
07 Nov 2006	Genentech Announces Manufacturing Agreements With Lonza
10 Oct 2006	Genentech Announces Third Quarter 2006 Results
11 Oct 2006	FDA Approves Avastin in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
04 Oct 2006	New England Journal of Medicine Publishes Data From Lucentis Pivotal Phase III Studies in Wet Age-Related Macular Degeneration
04 Oct 2006	Genentech Announces Vice President Appointments in Commercial Operations and Manufacturing
03 Oct 2006	Genentech and CGI Pharmaceuticals Enter Into Exclusive Global Strategic Alliance for Potential Products in Multiple Oncology and Autoimmune Indications
29 Sep 2006	FDA Approves Two New Indications for Rituxan in Patients With Non-Hodgkin's Lymphoma
19 Sep 2006	Genentech Announces October 10 Webcast Discussion of Third Quarter Earnings and Other Business Results
11 Sep 2006	Genentech Receives Complete Response Letter From FDA for Avastin in Metastatic Breast Cancer
28 Aug 2006	Genentech and Biogen Idec Announce Positive Results from a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
17 Aug 2006	Genentech Foundation for Biomedical Sciences Awards $1.2 Million to Health Science Education Programs in the Bay Area
11 Aug 2006	Genentech Provides Update On Supplemental Biologics License Application For Adjuvant Herceptin In Early-Stage Her2-Positive Breast Cancer
26 Jul 2006	Genentech Announces Vice President and Officer Appointments in Product Development and Finance
25 Jul 2006	Genentech & Inotek Enter into Exclusive Global Strategic Alliance for the Discovery, Development and Commercialization of PARP Inhibitors for Cancer
11 Jul 2006	Genentech Announces Second Quarter 2006 Results
26 Jun 2006	Phase III Study of Avastin in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
22 Jun 2006	Analysis of Phase III Study Showed Rituxan Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
20 Jun 2006	FDA Approves Avastin in Combination with Chemotherapy for Second-Line Metastatic Colorectal Cancer Patients
20 Jun 2006	Genentech Announces July 11 Webcast Discussion of Earnings and Other Business Results
30 Jun 2006	FDA Approves LUCENTIS for the Treatment of Wet Age-Related Macular Degeneration
05 Jun 2006	Results From a Randomized Phase II Trial Suggested the Combinations of Avastin Plus Tarceva and Avastin Plus Chemotherapy Improved Progression-Free Survival in Advanced Non-Small Cell Lung Cancer
02 Jun 2006	Preliminary Results from a Phase IIIb Study Showed Patients with Wet AMD Treated with Lucentis Quarterly Experienced a 16-Letter Benefit over the Control Group at One Year
25 May 2006	Genentech Submits Supplemental Biologics License Application for Avastin with Chemotherapy in First-Line Metastatic Breast Cancer
22 May 2006	Genentech Announces June 5 Webcast Discussion of Data Presented at ASCO
22 May 2006	Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
19 May 2006	Genentech Announces June 2 Webcast Discussion Of Lucentis Data Presented At The 2006 Retinal Physician Symposium
11 May 2006	Genentech Announces Vice President Appointments In Commercial Operations And Product Development
21 Apr 2006	Genentech Extends Stock Repurchase Program
11 Apr 2006	Genentech Submits Supplemental Biologics License Application for Avastin with Chemotherapy in First-Line, Non-Squamous, Non-Small Cell Lung Cancer
11 Apr 2006	Genentech Announces First Quarter 2006 Results
10 Apr 2006	Genentech Announces Vice President Appointments in Commercial Operations and Product Development
30 Mar 2006	Genentech and Biogen Idec Submit Supplemental Biologics License Application for First-Line Use of Rituxan in Low-Grade or Follicular CD20-Positive B-Cell Non-Hodgkin's Lymphoma
23 Mar 2006	Genentech Announces April 11 Webcast Discussion of Earnings and Other Business Results
17 Mar 2006	Genentech Provides Updates at Annual Investment Meeting
03 Mar 2006	Genentech Announces March 17 Webcast of Investment Community Meeting
28 Feb 2006	Genentech Granted Six-Month Priority Review for Lucentis for the Treatment of Wet Age-Related Macular Degeneration
28 Feb 2006	FDA Approves Rituxan - The First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
15 Feb 2006	Genentech Submits Supplemental Biologics License Application for Adjuvant Herceptin in Early-Stage HER2-Positive Breast Cancer
12 Feb 2006	Recruitment Temporarily Suspended in an International Phase III Trial (AVANT) in Early-Stage Colon Cancer
10 Feb 2006	FDA Approves Rituxan Plus CHOP or other Anthracycline-Based Chemotherapy Regimens for First-Line Treatment of Diffuse Large B-Cell Non-Hodgkin's Lymphoma
26 Jan 2006	Amgen and Genentech Sign License Agreements for Antibody Patents
14 Jan 2006	Preliminary Phase III Data from Head-to-Head Study of Lucentis Shows Lucentis Improved Vision Compared to Visudyne in Patients with Wet Age-Related Macular Degeneration
10 Jan 2006	Genentech Announces Full Year and Fourth Quarter 2005 Results
09 Jan 2006	Genentech Named Number 1 on FORTUNE's 100 Best Companies to Work For
09 Jan 2006	Genentech Announces Vice President Appointments in Commercial Operations, Corporate Information Technology, Product Development and Product Operations
06 Jan 2006	Genentech Announces January 14th Webcast Discussion Of Data Presented At Macula 2006 Meeting
05 Jan 2006	Genentech Announces Executive Promotions
21 Dec 2005	Genentech Announces January 10 Webcast Discussion of Earnings and Other Business Results
30 Dec 2005	Genentech Submits Biologics License Application for FDA Review of Lucentis in Wet Age-Related Macular Degeneration
19 Dec 2005	Genentech Submits Supplemental Biologics License Application for Avastin in Relapsed Metastatic Colorectal Cancer
10 Nov 2005	Biogen Idec and Genentech Announce November 16th Webcast Discussion of Rituxan Data Presented at ACR
07 Nov 2005	Preliminary Data from Phase III Trial Show Lucentis is the First Investigational Therapy to Demonstrate Clinical Benefit over Visudyne in a Head-to-Head Study of Patients with Wet AMD
02 Nov 2005	FDA Approves Tarceva in Combination with Gemcitabine Chemotherapy for Treatment of Locally Advanced, Inoperable or Metastatic Pancreatic Cancer
31 Oct 2005	Biogen Idec and Genentech Announce FDA Acceptance of Supplemental Biologics License Application and Priority Review Designation for Rituxan in Rheumatoid Arthritis
25 Oct 2005	FDA Grants Priorty Review for Rituxan Supplemental Biologics License Application for Front-Line Treatment of Intermediate-Grade or Aggressive Non-Hodgkin's Lymphoma
19 Oct 2005	Genentech and ABC2 Announce Second Brain Cancer Collaboration
19 Oct 2005	Pivotal Herceptin Data in the New England Journal of Medicine Showed Significant Improvement in Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer
18 Oct 2005	Genentech Announces Preliminary Results from Randomized Phase II Trial of Avastin and Tarceva in Kidney Cancer
10 Oct 2005	Genentech Announces Third Quarter 2005 Results
27 Sep 2005	Genentech Provides Information on Patent Reexamination
23 Sep 2005	Genentech Provides Update on Phase II Study with Avastin in Platinum-Refractory Ovarian Cancer
19 Sep 2005	Genentech Announces October 10 Webcast Discussion of Earnings and Other Business Results
13 Sep 2005	FDA Advisory Panel Recommends Tarceva Approval for Pancreatic Cancer
13 Sep 2005	Fourth Phase III Study Shows Herceptin Plus Chemotherapy Improved Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer
07 Sep 2005	Genentech Announces Plans to File for FDA Approval of Lucentis for the Treatment of Wet Age-Related Macular Degeneration in December
31 Aug 2005	Biogen Idec and Genentech Submit a Supplemental Biologics License Application for FDA Review of Rituxan for the Treatment of Rheumatoid Arthritis
17 Aug 2005	Genentech and Biogen Idec File Supplemental Biologics License Application for FDA Review of Rituxan for Front-Line Treatment of Intermediate Grade or Aggressive CD-20-Positive, B-Cell, Non-Hodgkin's Lymphoma
16 Aug 2005	Genentech Announces Organizational Changes
29 Jul 2005	Genentech Foundation for Biomedical Sciences Bolsters Innovation in Health Science Education with $1.2 Million for Bay Area Programs
18 Jul 2005	Preliminary Phase I/II Study Showed Lucentis Improved Vision in Patients with Wet Age-Related Macular Degeneration When Used in Combination with Visudyne
18 Jul 2005	Phase III Study Shows Lucentis Improved Vision in Patients With Wet Age-Related Macular Degeneration
13 Jul 2005	Pivotal Phase III Tarceva Study Published in the New England Journal of Medicine Showed Survival Improvement in Advanced Non-Small Cell Lung Cancer
13 Jul 2005	Genentech Announces Pricing of $2 Billion in Senior Notes
13 Jul 2005	Genentech Announces Intention to Offer up to $2 Billion in Senior Notes
11 Jul 2005	Genentech Announces Second Quarter 2005 Results
05 Jul 2005	Genentech Announces July 18 Webcast Discussion of Data Presented at ASRS
28 Jun 2005	Genentech Announces Vice President Appointments in Product Operations, Regulatory, and Research
24 Jun 2005	Genentech Provides Manufacturing Update
23 Jun 2005	Genentech Announces June 24 Webcast Discussion of Recent Manufacturing Activities
20 Jun 2005	Genentech Announces July 11 Webcast Discussion of Earnings and Other Business Results
16 Jun 2005	Biologics Manufacturing Facility to be Purchased by Genentech from Biogen Idec
15 Jun 2005	Genentech Extends Share Repurchase Program
09 Jun 2005	Preliminary Phase IIb Study Showed Rituxan Improved Symptoms in Rheumatoid Arthritis Patients Who Failed One or More Disease-Modifying Anti-Rheumatic Drugs
31 May 2005	Preliminary Phase I/II Data Show Lucentis in Combination With Visudyne Maintained or Improved Vision in Approximately 90 Percent of Patients With Wet Age-Related Macular Degeneration
23 May 2005	Preliminary Phase III Data Show Lucentis Maintained or Improved Vision in Nearly 95 Percent of Patients with Wet Age-Related Macular Degeneration
15 May 2005	Data From Omnitarg Clinical Program Presented at American Society of Clinical Oncology Meeting
14 May 2005	Phase III Study of Tarceva in Combination with Chemotherapy Improves Survival in Pancreatic Cancer Patients
13 May 2005	Herceptin Plus Chemotherapy Improved Disease-Free Survival and Overall Survival in Adjuvant Setting for Early-Stage Her2-Positive Breast Cancer Patients
13 May 2005	Avastin Plus Chemotherapy Showed Doubling of Time Without Cancer Progression in Phase III Trial of First-Line Metastatic Breast Cancer Patients
13 May 2005	Phase III Trial of Avastin Plus Chemotherapy Showed 30 Percent Improvement in Overall Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
04 May 2005	Genentech Announces Webcast Discussions of Data Presented at ASCO; Phase III Breast Cancer Studies to be Presented at Educational Session
04 May 2005	Genentech Announces Vice President Appointments in Product Operations and Product Development
02 May 2005	OSI Pharmaceuticals and Genentech Announce Filing of a Supplemental New Drug Application to the FDA for Tarceva in Pancreatic Cancer
25 Apr 2005	Interim Analysis of Phase III Studies Shows Herceptin Plus Chemotherapy Improves Disease-Free Survival in the Adjuvant Setting for Early-Stage HER2-Positive Breast Cancer Patients
14 Apr 2005	Interim Analysis of Phase III Trial Shows Avastin Plus Chemotherapy Improved Progression-Free Survival in Patients with First-Line Metastatic Breast Cancer
11 Apr 2005	Genentech Announces First Quarter 2005 Results
05 Apr 2005	Phase III Study Shows Rituxan Significantly Improves Symptoms in Patients with Rheumatoid Arthritis Who Inadequately Responded to Anti-TNF Therapies
21 Mar 2005	Genentech Announces April 11 Webcast Discussion of Earnings and Other Business Results
21 Mar 2005	Genentech and Ipsen Agree to Develop Sustained-Release Formulations of Recombinant Human Growth Hormone
14 Mar 2005	Interim Analysis of Phase III Trial Shows Avastin Plus Chemotherapy Extends Survival of Patients with First-Line Non-Squamous, Non-Small Cell Lung Cancer
04 Mar 2005	Genentech Announces Strategic Updates at Investment Meeting
25 Feb 2005	Genentech Announces March 4 Webcast of Investment Community Meeting
18 Feb 2005	Three-Year Study with Raptiva Showed Long-Term and Sustained Clearing in Moderate-to-Severe Plaque Psoriasis Patients
27 Jan 2005	Data From Phase III Study Show Tarceva Plus Gemcitabine Significantly Improves Survival Compared to Gemcitabine Alone in Advanced Pancreatic Cancer Patients
27 Jan 2005	Preliminary Positive Results from Phase III Trial of Avastin Plus FOLFOX4 Chemotherapy Presented at ASCO GI Meeting
10 Jan 2005	Genentech Announces Fourth Quarter and Full Year 2004 Results
10 Jan 2005	Genentech Again Named One of FORTUNE's "100 Best Companies To Work For"
06 Jan 2005	Genentech Finalizes Avastin Label with Previously Announced Safety Information
22 Dec 2004	Genentech Board Announces Executive Promotions and Senior Appointments in Commercial Operations, Finance and Manufacturing
21 Dec 2004	Genentech Announces January 10 Webcast Discussion of Earnings and Other Business Results
29 Nov 2004	Phase III Results Show Avastin Plus Folfox4 Chemotherapy Significantly Extend Survival in Second-Line Metastatic Colorectal Cancer
25 Nov 2004	Genentech Again Named the No. 1 Employer in Science Magazine Survey
18 Nov 2004	Genentech Announces November 18 Webcast Discussion of Tarceva FDA Approval
18 Nov 2004	FDA Approves Tarceva for Patients with Advanced Non-Small Cell Lung Cancer
10 Nov 2004	Genentech Announces Organizational Changes
09 Nov 2004	Genentech and Rinat Neuroscience Announce Co-Development and Joint Commercialization Agreement for Anti-NGF Antibody for Acute and Chronic Pain
04 Nov 2004	Genentech Announces Senior Appointments in Manufacturing and Engineering
01 Nov 2004	Preliminary Phase IIb Data Show Rituxan Improved Symptoms in Patients with Moderate-to-Severe Rheumatoid Arthritis
21 Oct 2004	Genentech to Seek Review of Court Decision in Contract Dispute
06 Oct 2004	Genentech Announces Third Quarter 2004 Results
04 Oct 2004	Genentech Receives Subpoena on Rituxan
28 Sep 2004	Genentech Extends Share Repurchase Program
23 Sep 2004	Genentech and Wyeth Announce Manufacturing Agreement
20 Sep 2004	Tarceva Plus Gemcitabine Improves Survival Compared to Gemcitabine Alone in First-Line Pancreatic Cancer Patients
15 Sep 2004	Genentech Announces October 6 Webcast Discussion of Earnings and Other Business Results
10 Sep 2004	Genentech and OSI Pharmaceuticals Initiate Phase IIIB Clinical Trial of Tarceva in Advanced Non-Small Cell Lung Cancer
02 Sep 2004	Giants and Genentech Devote Sunday, September 5 to Striking Out Cancer
10 Aug 2004	Genentech Announces FDA Approval of Avastin Manufacturing at Vacaville Facility
02 Aug 2004	OSI Pharmaceuticals and Genentech Announce Completion of New Drug Application for FDA Approval of Tarceva
29 Jul 2004	Preliminary Data Showed Sustained Clinical Benefit for Moderate-to-Severe Plaque Psoriasis Patients Treated with Raptiva for 30 Months
07 Jul 2004	Genentech Announces Second Quarter 2004 Results
30 Jun 2004	Genentech Announces Senior Appointments in Commercial Operations and Development
17 Jun 2004	Genentech Announces July 7 Webcast Discussion of Earnings and Other Business Results
16 Jun 2004	Positive Data from Preliminary Phase II Study of Rituxan in Rheumatoid Arthritis Published in the New England Journal Of Medicine
16 Jun 2004	OSI Pharmaceuticals and Genentech Enter into Co-Promotion and Manufacturing Agreements for Tarceva
05 Jun 2004	Phase III Study of Tarceva in Relapsed Non-Small Cell Lung Cancer Shows Significant Improvement in Survival
08 Jun 2004	Genentech Presents Data from Broad Avastin Clinical Trial Program at the American Society of Clinical Oncology Meeting
07 Jun 2004	Key Herceptin Data Presented at American Society of Clinical Oncology Meeting
05 Jun 2004	Early Clinical Data Evaluating the Combination of Avastin and Tarceva Yield Initial Promising Results in Several Cancers
05 Jun 2004	Preliminary Results of a Phase III Study Showed Rituxan Maintenance Therapy Improved Progression-Free Survival in Newly Diagnosed Patients with Indolent Non-Hodgkin's Lymphoma
05 Jun 2004	Preliminary Phase III Data Showed Front-Line Use of Rituxan Plus Chemotherapy Improved Survival in Patients Under 60 with Aggressive Non-Hodgkin's Lymphoma
02 Jun 2004	Pivotal Avastin Study in New England Journal of Medicine Showed Significant Improvement in Patients with Metastatic Colorectal Cancer
01 Jun 2004	Genentech and Alkermes Announce Decision to Discontinue Commercialization of Nutropin Depot
21 May 2004	Genentech Announces Webcast Discussions of Data Presented at ASCO
18 May 2004	Genentech Foundation for Biomedical Sciences Awards More Than $1 Million to Science Education Programs in the Bay Area
25 Apr 2004	Tarceva Extends Survival of Patients with Relapsed Non-Small Cell Lung Cancer
16 Apr 2004	Genentech Announces Approval of Two-for-One Stock Split
07 Apr 2004	Genentech Announces First Quarter 2004 Results - Increase of 28 Percent in Product Sales
06 Apr 2004	Genentech Win in Chiron Patent Litigation Unanimously Affirmed by U.S. Court of Appeals
24 Mar 2004	Genentech Announces Senior Appointment in Corporate Information Technology
21 Mar 2004	Genentech and XOMA Announce Results of Phase II Study of Raptiva in Psoriatic Arthritis Patients
12 Mar 2004	Genentech Announces Long-Term Strategy and Financial Goals
10 Mar 2004	Genentech Announces April 7 Webcast Discussion of Earnings and Other Business Results
09 Mar 2004	Genentech Announces Organizational Changes
03 Mar 2004	Genentech's Board of Directors Approves a Conditional Stock Split
02 Mar 2004	Genentech Announces March 12 Webcast of Investment Community Meeting
26 Feb 2004	FDA Approves Avastin, a Targeted Therapy for First-Line Metastatic Colorectal Cancer Patients
26 Feb 2004	Genentech, Novartis and Tanox Settle Disputes Surrounding Xolair and TNX-901
16 Jan 2004	Genentech Announces Senior Appointments in Development, Commercial and Manufacturing
14 Jan 2004	Genentech Reports $3.3 Billion in Revenues with $1.9 Billion in Oncology Sales
07 Jan 2004	Genentech Announces Webcast of Presentation at JP Morgan 22nd Annual Healthcare Conference
29 Dec 2003	Genentech Named Number 15 on Fortune's "Best Companies To Work For" List
15 Dec 2003	Genentech and Lonza Announce Manufacturing Agreement
15 Dec 2003	Genentech Announces January 14 Webcast Discussion of Earnings and Other Business Results
07 Dec 2003	Phase III Trial of Rituxan Plus Chemotherapy as a Front-Line Therapy in Aggressive Non-Hodgkin's Lymphoma Reaches Pre-Specified Efficacy Endpoint Two Years Early
08 Dec 2003	Initial Results of a Randomized Phase II Study Suggest that Rituxan Maintenance Therapy Prolongs Remission in Indolent NHL
07 Dec 2003	Initial Results of a New Study of Rituxan Plus CVP Chemotherapy Demonstrate Prolonged Time to Treatment Failure as Front-Line Therapy for Patients with Indolent Non-Hodgkin's Lymphoma
07 Dec 2003	Initial Data from Phase III ECOG 4494 Study of Rituxan as Front-Line and Maintenance Therapy in Aggressive Non-Hodgkin's Lymphoma (NHL) Presented at ASH
05 Dec 2003	Genentech Announces Share Repurchase Program
04 Dec 2003	Preliminary Results of a Phase II Study of Herceptin and Taxotere (docetaxel) Combination Suggests Improved Survival in HER2-Positive Metastatic Breast Cancer Patients
01 Dec 2003	Genentech Announces FDA Acceptance of Biologics License Application with Priority Review of Avastin In First-Line Metastatic Colorectal Cancer
24 Nov 2003	Genentech Announces December 7th Webcast Discussion of Data Presented at ASH
25 Nov 2003	Genentech Reports Results from Phase II Trial of Avastin in Metastatic Colorectal Cancer
19 Nov 2003	Study in New England Journal of Medicine Shows Extending Raptiva (efalizumab) Treatment Provides Rapid and Continuous Benefit
13 Nov 2003	Eastern Cooperative Oncology Group (ECOG) Phase III Trial of Rituxan Maintenance Therapy in Indolent Non-Hodgkin's Lymphoma Reaches Pre-Specified Efficacy Endpoint Early
11 Nov 2003	Boehringer Ingelheim and Genentech Announce Initiation of a Clinical Trial Evaluating TNKase/Metalyse Use Prior to Angioplasty for Treatment of Heart Attack
10 Nov 2003	Genentech Named to "Scientific American 50" List
04 Nov 2003	Initial Data Released From Phase III ECOG 4494 Study of Rituxan as Front-Line and Maintenance Therapy in Aggressive Non-Hodgkin's Lymphoma
26 Oct 2003	Follow-Up Data from Phase II Study of Rituxan as a Potential Treatment for Rheumatoid Arthritis Show Durability of Response at 48 Weeks
23 Oct 2003	Genentech Named the No. 1 Rated Employer in Science Magazine Survey
27 Oct 2003	FDA Approves Raptiva (efalizumab) for Chronic Moderate-to-Severe Plaque Psoriasis
08 Oct 2003	Genentech Reports 17 Percent Increase in Non-GAAP Earnings Per Share for Third Quarter 2003
07 Oct 2003	Genentech Announces Senior Appointments in Commercial Operations and Research
01 Oct 2003	Phase III Trials of Tarceva(TM) Plus Chemotherapy in First-Line Non-Small Cell Lung Cancer Do Not Meet Primary Efficacy Endpoint
29 Sep 2003	Genentech Files Biologics License Application for FDA Approval of Avastin in First-Line Metastatic Colorectal Cancer
24 Sep 2003	Genentech Announces October 8 Webcast Discussion of Earnings and Other Business Results
09 Sep 2003	FDA Advisory Committee Unanimously Recommends Approval for Raptiva as a Potential Treatment for Moderate-to-Severe Plaque Psoriasis
03 Sep 2003	Genentech Promotes Richard Scheller to Executive Vice President, Research
03 Sep 2003	Genentech Appoints Marc Tessier-Lavigne to Senior Vice President, Research Drug Discovery
02 Sep 2003	Genentech Announces September 9th Webcast Discussion of DODAC Review of Raptiva BLA
27 Aug 2003	Genentech and Amgen Settle Patent Dispute
18 Aug 2003	Genentech Presents Positive Preliminary Six-Month Data from Phase Ib/II Study for Lucentis in Age-Related Macular Degeneration (AMD)
08 Aug 2003	Tarceva (erlotinib HCl) Phase II Clinical Trial Initiated in Patients with Malignant Glioma
31 Jul 2003	Genentech and XOMA Announce FDA Advisory Committee Review of Raptiva
26 Jul 2003	New Data Support Raptiva as a Potential Long-Term Treatment for Moderate-to-Severe Plaque Psoriasis
17 Jul 2003	Genentech Announces Senior Appointments in Research and Commercial Operations
09 Jul 2003	Genentech Reports 35 Percent Increase in Non-GAAP Earnings Per Share for Second Quarter
26 Jun 2003	Genentech Receives FDA Fast-Track Designation for Avastin
25 Jun 2003	Genentech Announces July 9 Webcast Discussion of Earnings and Other Business Results
24 Jun 2003	Genentech and Novartis Ophthalmics Announce Development and Commercialization Agreement for Age-Related Macular Degeneration Treatment, Lucentis
20 Jun 2003	Genentech and IDEC Announce Humanized Anti-CD20 Antibody Development Collaboration
20 Jun 2003	FDA Approves Xolair, Biotechnology Breakthrough for Asthma
17 Jun 2003	Genentech and Biogen Announce Autoimmune Collaboration
01 Jun 2003	Positive Results from Phase III Avastin Study in Metastatic Colorectal Cancer Presented at ASCO
02 Jun 2003	Clinical Data from Phase II Study in Early Breast Cancer Suggest Potential Use of Herceptin with New Chemotherapy Combination
01 Jun 2003	Genentech Reports Additional Data from BioOncology Pipeline at ASCO
31 May 2003	Tarceva (erlotinib HCl) Shows Encouraging Safety Profile and Activity in Phase I Clinical Study in Patients with Malignant Glioma
31 May 2003	Preliminary Positive Data From Rituxan Multi-Center Trial in First-Line and Maintenance Therapy in Patients with Chronic Lymphocytic Leukemia (CLL)
29 May 2003	Genentech Names Corsee Sanders Vice President, Biometrics and Business Operations, Medical Affairs
23 May 2003	Genentech Announces June 1st Webcast Discussion of Data Presented at ASCO
19 May 2003	Phase III Trial of Avastin Plus Chemotherapy Markedly Extends Survival of Metastatic Colorectal Cancer Patients
15 May 2003	FDA Advisory Committee Unanimously Recommends Approval of Xolair
12 May 2003	Genentech and XOMA Discontinue Rheumatoid Arthritis Trial
08 May 2003	Genentech Announces May 15th Webcast Discussion of PADAC Review of Xolair BLA
08 May 2003	Genentech And ABC(2) Agree to Collaborate on Brain Cancer Clinical Trial
16 Apr 2003	Genentech Announces April 23 Webcast of Annual Meeting of Stockholders
10 Apr 2003	Genentech Foundation for Biomedical Sciences Awards $1 Million to Science Education Programs in the Bay Area
09 Apr 2003	Genentech Reports 59 Percent Increase in Non-GAAP Earnings Per Share for First Quarter
26 Mar 2003	Genentech Announces April 9 Webcast Discussion of Earnings and Other Business Results
27 Mar 2003	Genentech, Novartis and Tanox Announce FDA Advisory Committee Review of Xolair (Omalizumab)
22 Mar 2003	Preliminary Results from Open-Label Raptiva Study Suggest Continued Benefit with Long-Term Treatment
21 Mar 2003	Phase III Study Results with Raptiva in the Treatment of Psoriasis Presented at Annual AAD Meeting
14 Mar 2003	Genentech Projects Double-Digit Growth for 2005-2010
12 Mar 2003	Genentech Appoints Philippa Norman Vice President, Global Supply Chain
07 Mar 2003	Genentech Announces March 21 Webcast Discussion of Data Presented at the American Academy of Dermatology
03 Mar 2003	Genentech Announces March 14 Webcast of Investment Community Meeting
27 Jan 2003	Genentech Appoints Ian Clark Senior Vice President and General Manager, BioOncology
15 Jan 2003	Genentech Exceeds $2.7 Billion in Revenues with $1.5 Billion in Oncology Sales
06 Jan 2003	Genentech Announces Webcast of Presentation at JP Morgan 21st Annual Healthcare Conference
06 Jan 2003	Genentech Named One of Fortune's "100 Best Companies To Work For"
02 Jan 2003	Genentech Announces January 15 Webcast Discussion of Earnings and Other Business Results
23 Dec 2002	Genentech and XOMA Submit Biologics License Application for FDA Approval of Raptiva(TM) (Efalizumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis
18 Dec 2002	Genentech and Novartis Submit Amendment to the Biologics License Application for Xolair (TM) (Omalizumab) to FDA
11 Dec 2002	Preliminary Results from Phase III Study Demonstrate Herceptin/Chemotherapy Combination Delays Time to Disease Progression in HER2-Positive Breast Cancer
09 Dec 2002	Investigational Data Demonstrate Potential of Extended Rituxan(R) Use to Increase Event-Free Survival in Patients with Indolent NHL
20 Nov 2002	Pre-Hospital Thrombolytic Treatment of Heart Attack Found Feasible and Faster Than In-Hospital Therapy
28 Oct 2002	Preliminary Positive Data from Investigational Randomized Phase II Trial Demonstrates Rituxan as a Potential Treatment for Rheumatoid Arthritis
09 Oct 2002	Genentech Reports 23 Percent Increase in Product Sales for Third Quarter
29 Apr 1983	Genentech Reports First Quarter Results
07 Oct 2002	Genentech Announces Senior Appointments in Medical Affairs and Research
01 Oct 2002	Genentech Announces Preliminary Positive Phase Ib/II Data for rhuFab V2 in Age-Related Macular Degeneration (AMD)
26 Sep 2002	Genentech Announces October 9 Webcast Discussion of Earnings and Other Business Results
24 Sep 2002	Genentech Recognized as One of The 100 Best Companies for Working Mothers
19 Sep 2002	Genentech Listed as Top Employer in Science Survey
17 Sep 2002	Genentech and XOMA Announce Phase III Study with Raptiva(TM) Achieves Primary Efficacy Endpoint
09 Sep 2002	Phase III Trial With Avastin(TM) in Relapsed Metastatic Breast Cancer Does Not Meet Primary Endpoint
06 Sep 2002	Genentech Wins Patent Dispute With Chiron
04 Sep 2002	Genentech Names Stephen G. Juelsgaard Executive Vice President
29 Aug 2002	Genentech Receives FDA Approval to Include HER2 Gene Detection Test in Herceptin(R) Product Labeling
19 Aug 2002	OSI Pharmaceuticals and Genentech Provide Update on Status of Tarceva Program
19 Aug 2002	Genentech Extends Stock Repurchase Program
15 Aug 2002	U.S. PTO Interference Declared in Genentech/Chiron Patent Dispute
07 Aug 2002	Serono and Genentech Announce International Marketing Agreement for Psoriasis Treatment Raptiva
01 Aug 2002	Tarceva U.S. Phase III Non-Small Cell Lung Cancer Clinical Trial Completes Patient Enrollment
02 Aug 2002	Genentech and XOMA Announce Preliminary Data from Long-Term Study with Investigational Psoriasis Therapy
10 Jul 2002	Genentech Reports 28 Percent Increase in Product Sales for Second Quarter
20 Jun 2002	Genentech Announces July 10 Webcast Discussion of Earnings and Other Business Results
24 Jun 2002	Genentech to Appeal Judgment in Contract Dispute
18 Jun 2002	Preliminary Data from Phase II Study of Rituxan for Rheumatoid Arthritis are Positive
17 Jun 2002	Investigational Data from Randomized Study of Extended Therapy with Rituxan(R) Demonstrates Potential to Delay Disease Progression in Patients with Indolent NHL
10 Jun 2002	Genentech Announces Verdict in Contract Dispute
21 May 2002	Investigational Data Demonstrates Potential Use of Rituxan in Various CD20-Positive Cancers
20 May 2002	National Cancer Institute (NCI) Study Demonstrates Genentech's Investigational Anti-Angiogenesis Treatment Avastin(TM) Delays Time to Disease Progression in Metastatic Kidney Cancer
14 May 2002	Genentech Appoints Hal Barron Vice President, Medical Affairs
14 May 2002	Genentech and OSI Pharmaceuticals Announce FDA Fast-Track Designation for Tarceva(tm)
09 May 2002	Genentech Invites Investors to Listen to Webcast of May 21 Discussion of ASCO Presentations
23 Apr 2002	FDA Approves Nutropin AQ PEN (TM) For Delivery Of Nutropin AQ (R) Recombinant Growth Hormone
22 Apr 2002	Genentech Foundation for Biomedical Sciences Awards $869,411 to Support Quality Science Education in the Bay Area
09 Apr 2002	Genentech Reports 22 Percent Increase in Product Sales For First Quarter
05 Apr 2002	Genentech and Xoma Obtain Results from Xanelim(TM) (Efalizumab) Pharmacokinetic Study
25 Mar 2002	Genentech Announces April 9 Webcast Discussion of Earnings and Other Business Results
14 May 1999	Phase III Trial with Anti-IgE Shows Positive Results in Treating Seasonal Allergic Rhinitis
15 May 1999	Follow-Up Data Shows Improvement in Overall Survival in Metastatic Breast Cancer Patients Treated with Herceptin, Plus Chemotherapy
19 May 1999	Genentech Confirms Growth Hormone Research Performed Independently; Seeburg Testimony is False
01 Jun 1999	Immunex Corporation and Genentech, Inc. Join Forces To Develop TRAIL/Apo2L in Cancer
02 Jun 1999	No Verdict Reached in Genentech, University of California Patent Infringement Case
02 Jun 1999	Genentech to Remain Independent Company, Roche Intends to Exercise Its Call Option and Publicly Reissue Genentech Shares
07 Jun 1999	Study Shows Simpler Procedures Employed by Industry-Sponsored Heart Attack Registry Are Comparable to More Complex Government Program
08 Jun 1999	Genentech and Immunex Announce Patent License Agreement for Immunoadhesin Technology for ENBREL
13 Jun 1999	Phase III Clinical Trial Shows Promising Results of Nutropin Depot
14 Jun 1999	SEC Registration Filed for Genentech Public Offering
14 Jun 1999	Roche Exercises Option to Redeem Genentech Shares
28 Jun 1999	Genentech and Alkermes Announce the Submission of a New Drug Application with the FDA for Nutropin Depot
30 Jun 1999	Genentech Scientists Receive Distinguished Inventor Award
01 Jul 1999	Genentech Appoints Diane Parks Vice President of Marketing

Our Pipeline

Our pipeline includes over 30 new molecular entities that address serious unmet medical needs.

Approvals Timeline

A look at our approvals past and present.

Press Releases

You Might Also Be Interested In

Our Pipeline

Approvals Timeline